Agree Realty Corporation — News

ADC delivered a strong Q2 with record acquisition activity, robust AFFO growth, and raised guidance across key metrics. ADC leverages a sector-leading cost of capital, maintaining a 150 basis point investment spread and a conservative balance sheet with net debt/EBITDA at 3.7x. External growth is fueled by aggressive equity issuance, but current valuation offers less yield than peers and is comparable to risk-free assets.

seekingalpha.com - 2026-08-01 09:41:13

Agree Realty Corporation (ADC) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-31 14:33:18

Agree Realty NYSE: ADC reported record second-quarter investment activity and raised its full-year outlook, citing strong acquisition, development and portfolio performance.

marketbeat.com - 2026-07-31 11:05:24

Agree Realty (ADC) came out with quarterly funds from operations (FFO) of $1.14 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to FFO of $1.06 per share a year ago.

zacks.com - 2026-07-30 20:31:22

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended June 30, 2026. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Second Quarter 2026 Financial and Operating Highlights: Invested a Company record of approximately $502 million in 102 retail net lease properties Commenced five development or Developer Funding Platform (“DFP”) projects for total committed capita.

businesswire.com - 2026-07-30 16:05:00

Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab tirumotecan (sac-TMT) Phase 2 trial in NSCLC, first ADC combination study in Kelun-Biotech collaboration, underway in China Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China; Phase 1/2 global trial of CR-002, a PD-L1-targeted ADC, on track to initiate in second half of 2026 Multiple key clinical data readouts across the portfolio anticipated beginning in Q1 2027 Completed $143.7 million public offering extending expected cash runway into the second half of 2028 WALTHAM, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the second quarter ended June 30, 2026 and recent business highlights.

globenewswire.com - 2026-07-30 07:35:00

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

zacks.com - 2026-07-28 09:56:48

For retirees who prefer their paychecks to arrive every 30 days instead of every 90, a small corner of the market delivers just that.

247wallst.com - 2026-07-27 11:28:01

Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significan

gurufocus.com - 2026-07-27 08:00:00

Realty Income (NYSE:O | O Price Prediction) gets most of the airtime in retiree circles, but it is not the only quality REIT engineered to write dividend checks year after year.

247wallst.com - 2026-07-26 08:00:50

California Public Employees Retirement System lessened its position in shares of Agree Realty Corporation (NYSE: ADC) by 7.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 276,624 shares of the real estate investment trust's stock after selling 23,684

defenseworld.net - 2026-07-23 03:41:51

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform

globenewswire.com - 2026-07-22 08:40:00

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose e

gurufocus.com - 2026-07-21 02:00:00

ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation

gurufocus.com - 2026-07-21 00:00:00

Agree Realty's Preferred Equity Series A offers a 6.1% yield, trading at a steep discount to call price, backed by a top-tier net lease REIT. ADC.PR.A provides monthly, cumulative dividends and strong downside protection, though lacks dividend growth and is sensitive to long-term rate increases. DIVO ETF delivers a 4.8% distribution yield via blue-chip dividend stocks and a conservative covered call strategy, maintaining low volatility and moderate upside cap.

seekingalpha.com - 2026-07-17 07:30:00

Few things ruin a Saturday morning faster than the words "your timing chain is going." Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those... The Portfolio That Pays All Your Car Repairs For Life

247wallst.com - 2026-07-16 13:47:38

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the third quarter of 2025. The dividend is payable August 14, 2026 to stockholders o.

businesswire.com - 2026-07-14 16:05:00

Retirement income requires more than just high yield. REIT funds may not be the best solution. A balanced REIT portfolio can offer income and growth.

seekingalpha.com - 2026-07-11 07:15:00

In the working world, paychecks show up every two weeks. Or at least, every month.

forbes.com - 2026-07-09 12:10:06

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

zacks.com - 2026-07-07 09:56:32

BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China. Developed from InnoCare's in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house invented payload via a protease-cleavable linker.

globenewswire.com - 2026-07-05 21:00:00

Income investors heading into July face a friendlier setup than they did just six weeks ago.

247wallst.com - 2026-07-05 09:00:05

Iron Mountain, Tanger, Four Corners, Essential Properties, and Chatham Lodging delivered outsized REIT returns by exploiting price-value gaps during market panics. My disciplined value investing approach focuses on durable business models, strong balance sheets, and buying below intrinsic value, not market timing or headline chasing. IRM and SKT now trade at premium valuations, while EPRT and FCPT remain attractively priced with solid growth and conservative payout ratios; CLDT reached fair value and was exited.

seekingalpha.com - 2026-07-04 08:00:00

LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on July 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.

prnewswire.com - 2026-07-01 16:05:00

Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its second quarter 2026 operating results after the market closes

gurufocus.com - 2026-06-30 17:01:00

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its second quarter 2026 operating results after the market closes on Thursday, July 30, 2026. A conference call to discuss the Company's operating results is scheduled for Friday, July 31, 2026, at 10:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (833) 461-5787 International (626) 884-3620  .

businesswire.com - 2026-06-30 16:05:00

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (r/r DLBCL). LOTIS-7 trial enrollment is now complete with 100 r/r DLBCL patients dosed at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab.

prnewswire.com - 2026-06-30 07:15:00

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-06-25 10:00:00

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026 LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA® (loncastuximab tesirine-lpyl) franchise. As part of the reorganization, ADC Therapeutics plans to reduce its workforce globally by approximately 17 percent.

prnewswire.com - 2026-06-24 07:30:00

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext. 7980.

globenewswire.com - 2026-06-23 17:50:00

AU, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)--Araris Biotech AG, a company advancing a differentiated pipeline of antibody-drug conjugates (“ADCs”) therapies, and Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, both members of the Taiho group, today announced that the first patient has been dosed in a Phase 1 clinical trial of ARC-02, a CD79b-targeted antibody-drug conjugate (ADC) for the treatment of non-Hodgk.

businesswire.com - 2026-06-23 09:00:00

PARIS--(BUSINESS WIRE)-- #adc--One Biosciences receives Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop first single-cell assay for antibody-drug conjugates therapies.

businesswire.com - 2026-06-22 16:15:00

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

zacks.com - 2026-06-19 09:56:14

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-06-18 10:00:00

Agree Realty is a high-quality net lease REIT with strong exposure to investment-grade, necessity-based retail tenants and a robust development platform. ADC delivered 7.9% YoY AFFO per share growth in Q1 2026, with a 104% rent recapture rate and active capital recycling supporting bottom-line expansion. I maintain a "buy" rating on ADC, citing its 4.3% yield, conservative 3.2x net debt/EBITDA, and well-covered 70% payout ratio.

seekingalpha.com - 2026-06-18 09:00:00

ZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform and its potential to enable more precise and targeted cancer therapies. VERAXA will attend the BIO International Convention in San Diego, Calif.

globenewswire.com - 2026-06-18 07:00:00

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.

prnewswire.com - 2026-06-17 09:00:00

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext. 7980.

globenewswire.com - 2026-06-16 17:36:00

HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in combination with ivonescimab for the treatment of advanced breast cancer. HER3 is broadly expressed across various solid tumors, including breast, ovarian, colon, gastric, lung, skin, and pancreatic cancers, affecting millions of patients globally.

prnewswire.com - 2026-06-15 02:52:00

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-06-11 10:00:00

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Opht

gurufocus.com - 2026-06-11 04:00:00

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext. 7980.

globenewswire.com - 2026-06-09 13:20:00

Agree Realty (NYSE:ADC) and Global Net Lease (NYSE:GNL) own the same kind of asset — single-tenant properties leased on long-term, triple-net terms — and report it very differently.

benzinga.com - 2026-06-09 10:09:33

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License Appl

gurufocus.com - 2026-06-08 21:00:00

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. The dividend is payable July 15, 2026 to stockholders of.

businesswire.com - 2026-06-08 16:05:00

Inflation relentlessly erodes purchasing power, making dividend growth essential for income investors to maintain real income. A barbell strategy—combining moderate-yielding dividend growth stocks/ETFs and 6.5%+ yielding investment grade preferreds—offers both growth and current income. AI-driven capex by large-cap S&P 500 firms is powering economic growth and masking weakness among lower-income consumers.

seekingalpha.com - 2026-06-06 08:15:00

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

seekingalpha.com - 2026-06-05 18:19:56

REITs (XLRE) may face another sector-wide pullback due to rising bond yields and inflation driven by Middle East conflict. CareTrust REIT and Agree Realty stand out for quality, growth, and strong balance sheets, but current valuations demand patience. CareTrust REIT stands out for its strong acquisition-driven growth, investment-grade upgrade, and robust balance sheet but is currently expensive at 19.63x earnings.

seekingalpha.com - 2026-06-05 07:45:00

Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential

globenewswire.com - 2026-06-04 09:30:00

ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study testing its blood cancer drug showed more deaths among ​treated patients, despite meeting its main goal of improving progression-free survival.

reuters.com - 2026-06-04 08:02:59